From simplicity to complexity: how excipients shape stability and disintegration of immediate-release tablets

Isra Tayseer(University of Strathclyde), Daniel Markl(University of Strathclyde), Adrian Davis(Anglia Ruskin University), Ibrahim Khadra(University of Strathclyde), Fredrik Winge(AstraZeneca (Netherlands)), Milena Virrankoski(Takeda (Japan)), James Mann(AstraZeneca (United Kingdom)), Austin DeAngelis(Takeda (Japan)), Bart Hens(Pfizer (Belgium))

International Journal of Pharmaceutics

June 22, 2026

10.1016/j.ijpharm.2026.127130

Cited by 0

Related Papers

A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010

|The Lancet|2012|12k

Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013

|The Lancet|2015|6.5k

UK health performance: findings of the Global Burden of Disease Study 2010

|The Lancet|2013|557

Acceptability, benefit and costs of early screening for hearing disability: a study of potential screening tests and models

|Health Technology Assessment|2007|432

Changes in health in the countries of the UK and 150 English Local Authority areas 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016

|The Lancet|2018|267